stockrow
Friday 6 November 2026
Export KZIA’s income statement to Excel — free account
Novogen Limited
KZIA Healthcare Biotechnology
Novogen Limited’s revenue for fiscal 2025 (year ended June 2025) was $1.2 million, down 24.7% from fiscal 2024.
7.22
0.22
+3.14%
Follow KZIA
Alert me
Novogen Limited (KZIA) P/E ratio
Novogen Limited has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2021 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NRXS Neuraxis, Inc. compare | n/m |
| GNLX Genelux Corporation compare | n/m |
| EQ Equillium, Inc. compare | n/m |
| CLLS Cellectis S.A. compare | n/m |
| TNXP Tonix Pharmaceuticals Holding Corp. compare | n/m |
| KZIA Novogen Limited | n/m |
| ATRA Atara Biotherapeutics, Inc. compare | n/m |
| TLSA Tiziana Life Sciences Ltd compare | n/m |
| RLYB Rallybio Corporation compare | 3.3× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)